Compare Alliant Energy Corporation (LNT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Alliant Energy Corporation trades at $67.51 (market cap $17.36B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Alliant Energy Corporation is far larger — about 3.6× Travere Therapeutics Inc. Common Stock's market cap, and Alliant Energy Corporation pays a 3.2% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 65 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LNT | TVTX | |
|---|---|---|
Market Cap | $17.36B | $4.88B |
Volume | 1,948,386 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $78.03 | $67.52 |
52-Week Low | $63.21 | $26.79 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $29.46B | $5.01B |
Dividend Yield | 3.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $67.51, up 1.58% with a bullish technical signal despite mixed momentum indicators. The company shows solid fundamentals with Q2 2026 earnings beating expectations at $0.65 per share and maintaining 18.45% net margins. Recent news highlights institutional accumulation and a $13.4 billion capital investment plan through 2029 supporting long-term growth. Analyst consensus remains positive with a $75.17 price target and no sell ratings.
LNT presents a favorable risk-reward profile with strong utility operations, consistent dividend growth, and data center demand driving revenue. Key risks include rising debt levels (48.48% debt-to-asset ratio) and interest rate sensitivity. The stock offers defensive value with upside potential to analyst targets, though investors should monitor execution of the large capex plan and regulatory developments.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
